Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received ≥ 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36.3%) required treatment at the time of diagnosis, four patients (3.8%) received first-line treatment during follow-up and 31 (56.3%) patients were followed without any treatment. Thirteen patients required second step treatment after a median of 26.3 months. The risk of progression was found to be increased 5-fold (p = 0.015) in the CD38 positive patient group, 4.2-fold (p = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold (p = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for ≥ 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105:1684–1692. https://doi.org/10.1038/bjc.2011.450
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1):198
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al (2008) International workshop on chronic lymphocytic leukemia, guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446
Diehl LF, Ketchum LH (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25(1):80
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21(5):956
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon
Rai KR, Montserrat E (1987) Prognostic factors in chronic lymphocytic leukemia. Semin Hematol 24(4):252–256
Molica S, Alberti A (1987) Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 60(11):2712
Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62(3):567
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526(7574):525–530
Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG et al (2014) Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 167(2):224–232
Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA et al (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679
Mina A, Sandoval Sus J, Sleiman E, Pinilla-Ibarz J, Awan FT, Kharfan-Dabaja MA (2017) Using prognostic models in CLL to personalize approach to clinical care: are we there yet? Blood Rev. https://doi.org/10.1016/j.blre.2017.10.003
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840
Dürig J, Nückel H, Cremer M, Führer A, Halfmeyer K, Fandrey J et al (2003) ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17(12):2426
Moreno C, Montserrat E (2008) New prognostic markers in chronic lymphocytic leukemia. Blood Rev 22:211–219
Delgado J, Matutes E, Morilla AM, Morilla RM, Owusu-Ankomah KA et al (2003) Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. FMedSci. https://doi.org/10.1309/fngcyemje3mae5l2
Wormsley SB, Baird SM, Gadol N, Rai KR, Sobol RE (1990) Characteristics of CD1 lc + CDS + chronic B-cell leukemias and the identification of novel peripheral blood b-cell subsets with chronic lymphoid leukemia ımmunophenotypes. Blood 76:123–130
Pinilla-Ibarz J, Emole J (2015) Chronic lymphocytic leukemia in the elderly, which investigations are necessary: a map for the practicing oncologist. Cancer Control 22(4 Suppl):7–16
Hamed NAM (2017) Treatment of chronic lymphocytic leukemia in the elderly, Alexandria University, Egypt Submission 10 Mar 2017; Published: 16 Mar 2017
Balducci L, Dolan D (2015) Chronic lymphocytic leukemia in the elderly: epidemiology and proposed patient-related approach. Cancer Control 22(4 Suppl):3–6
Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW et al (1987) Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47(3):830
Postigo AA, Corbi AL, Sanche-Madrid F, Landazuri MO (1991) Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18. J Exp Med 174(12):1313–1322
Sivakumaran S, Henderson S, Ward S, Sousa PS, Manzo T, Zhang L et al (2016) Depletion of CD11c+ cells in the CD11c.DTR model drives expansion of unique CD64+ Ly6C+ monocytes that are poised to release TNF-α. Eur J Immunol 46(1):192–203. https://doi.org/10.1002/eji.201545789
Umit EG, Baysal M, Durmus Y, Demir AM (2017) CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival. Int J Lab Hematol 39(5):552–556. https://doi.org/10.1111/ijlh.12695
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M et al (2015) ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(5):78–84. https://doi.org/10.1093/annonc/mdv303
Reddy P, Dabbas B, Gama M, Kocher T, Drum H, Taylor J et al (2012) FMC-7 expression identifies phenotypically atypical chronic lymphocytic leukemia with distinct clinical and molecular genetic features. Blood 120(21):2478
Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M (1990) Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 76(3):352–358
Mainou-Fowler T, Dignum H, Taylor PR, Dickinson AM, Saunders PW, Proctor SJ et al (2002) Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 118(3):755
Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD et al (2007) ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 13(18 Pt 1):5295
Meyerson HJ, Dalia SM, Koc ON, Fu P, Cocco AE (2004) Cellular expression of CD23, CD71, and CD38 are ındependent prognostic variables in B-cell chronic lymphocytic leukemia. Blood 104(11):47–5313
D’Arena G, Musto P, Cascavilla N, Dell’Olio M, Di Renzo N, Perla G et al (2001) CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 42(1–2):109
Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A et al (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16(1):30
The authors declared that this study has received no financial support.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Şentürk Yikilmaz, A., Akinci, S., Bakanay, Ş.M. et al. Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?. Indian J Hematol Blood Transfus 36, 84–90 (2020). https://doi.org/10.1007/s12288-019-01169-8